Janus Henderson Global Life Sciences Fund Class N Shares (JFNNX) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.83: the stock has moved about 17% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerJanus Henderson Global Life Sciences Fund Class N Shares (JFNNX) trades at $86.53. Janus Henderson Global Life Sciences Fund Class N Shares (JFNNX) is a financial services fund focused on investing in life science companies. Sector: Financials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for JFNNX: JFNNX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
Janus Henderson Global Life Sciences Fund Class N Shares (JFNNX) Financial Services Profile
Janus Henderson Global Life Sciences Fund Class N Shares (JFNNX) is a specialized fund targeting the life sciences sector, allocating at least 80% of its assets to companies with a life science orientation and 25% specifically within the life sciences sector, offering focused exposure to this dynamic industry.
What Is the Investment Thesis for JFNNX?
Janus Henderson Global Life Sciences Fund Class N Shares (JFNNX) presents an investment opportunity centered on the growth potential of the life sciences sector. With a beta of 0.83, the fund demonstrates moderate volatility relative to the broader market. The fund's strategy of allocating at least 80% of its assets to life science-oriented companies and a minimum of 25% to the core life sciences sector provides targeted exposure. Key value drivers include advancements in biotechnology, pharmaceutical innovation, and increasing demand for healthcare services globally. Upcoming catalysts include potential breakthroughs in gene therapy and personalized medicine, which could drive significant growth for portfolio companies. However, potential risks include regulatory hurdles, clinical trial failures, and competitive pressures within the industry. The fund's success depends on the portfolio managers' ability to identify and capitalize on promising opportunities while effectively managing risk.
Based on FMP financials and quantitative analysis
JFNNX Key Highlights
The fund invests at least 80% of its net assets in securities of companies with a life science orientation.
- A minimum of 25% of the fund's total assets are invested in companies categorized in the 'life sciences' sector.
- The fund has a market capitalization of $5.54 billion, indicating its size and significance within the life sciences investment landscape.
- The fund's beta of 0.83 suggests it is less volatile than the overall market.
- The fund does not offer a dividend yield, focusing instead on capital appreciation.
Who Are JFNNX's Competitors?
JFNNX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CTCAX Columbia Global Technology Growth Fund | $139.42 | +0.82% | $6.27B | — |
| CTHRX Columbia Global Technology Growth Fund Institutional 2 Class | $152.57 | +0.83% | $6.38B | — |
| JAGLX Janus Henderson Global Life Sciences Fund | $85.96 | +0.62% | $5.74B | — |
| JAWWX Janus Henderson Global Research Fund - T Shares | $135.57 | +0.89% | $4.77B | — |
| JDWAX Janus Henderson Global Research Fund Class A | $138.10 | +0.89% | $4.77B | — |
| APO Apollo Global Management, Inc. | $115.35 | +1.17% | $66.4B | 55 5-pillar |
| ALTI AlTi Global, Inc. | $2.95 | +1.37% | $427M | — |
| GROW U.S. Global Investors, Inc. | $2.90 | +1.40% | $37.3M | 57 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are JFNNX's Key Strengths?
Specialized focus on the high-growth life sciences sector.
- Experienced portfolio management team with expertise in healthcare investing.
- Established track record of delivering competitive investment performance.
- Diversified portfolio of life science stocks.
What Are JFNNX's Weaknesses?
Concentration risk due to focus on a single sector.
- Vulnerability to regulatory changes and clinical trial failures.
- Higher expense ratio compared to broader market index funds.
- Dependence on the performance of a limited number of holdings.
What Are the Key Risks for JFNNX?
Regulatory hurdles and clinical trial failures can negatively impact portfolio companies.
- Competitive pressures within the life sciences industry could erode market share.
- Economic downturns may reduce healthcare spending and investment.
- Dependence on key personnel and portfolio managers.
- Market volatility and fluctuations in stock prices.
What Threats Does JFNNX Face?
- Increased competition from other healthcare and biotechnology funds.
- Economic downturns that could negatively impact the healthcare industry.
- Changes in government regulations that could affect the profitability of portfolio companies.
- Unexpected clinical trial failures or product recalls.
What Are JFNNX's Competitive Advantages?
- Specialized Focus: The fund's focus on the life sciences sector provides a differentiated investment offering.
- Expertise: Janus Henderson's experience and expertise in asset management provide a competitive advantage.
- Established Brand: Janus Henderson is a well-known and respected name in the asset management industry.
- Scale: The fund's size allows it to access a wider range of investment opportunities.
What Does JFNNX Do?
Janus Henderson Global Life Sciences Fund Class N Shares (JFNNX) is a fund managed by Janus Henderson Investors, a global asset management group. The fund is designed to provide investors with targeted exposure to the life sciences sector. The fund operates under the principle of investing at least 80% of its net assets, plus any borrowings for investment purposes, in the securities of companies believed to have a life science orientation. This includes companies involved in biotechnology, pharmaceuticals, medical devices, and related fields. A key aspect of the fund's strategy is its commitment to investing at least 25% of its total assets in companies categorized specifically within the 'life sciences' sector. This ensures a core focus on the most relevant and innovative areas within the industry. The fund's investment decisions are guided by a team of portfolio managers who conduct in-depth research and analysis to identify companies with strong growth potential and sustainable competitive advantages. The fund's objective is to achieve long-term capital appreciation by capitalizing on the growth opportunities within the global life sciences market. JFNNX is available to investors seeking a specialized investment vehicle to participate in the potential of the life sciences industry.
What Products and Services Does JFNNX Offer?
- Invests in companies with a life science orientation.
- Allocates at least 80% of net assets to life science companies.
- Invests a minimum of 25% of total assets in the life sciences sector.
- Seeks long-term capital appreciation through investments in the life sciences industry.
- Conducts research and analysis to identify companies with growth potential.
- Manages a diversified portfolio of life science stocks.
- Provides investors with exposure to the biotechnology, pharmaceutical, and medical device industries.
How Does JFNNX Make Money?
- Generates revenue through management fees charged on assets under management (AUM).
- Aims to increase AUM by attracting new investors and retaining existing clients.
- Focuses on delivering competitive investment performance to justify management fees.
- Utilizes a team of portfolio managers and analysts to make investment decisions.
What Industry Does JFNNX Operate In?
Janus Henderson Global Life Sciences Fund Class N Shares (JFNNX) operates within the global asset management industry, specifically targeting the life sciences sector. The life sciences industry is characterized by rapid innovation, increasing healthcare demand, and evolving regulatory landscapes. The fund competes with other specialized healthcare and biotechnology funds, as well as broader market investment vehicles. The global asset management industry is experiencing growth driven by increasing wealth, aging populations, and the need for retirement planning. The fund's success depends on its ability to identify and capitalize on growth opportunities within the life sciences sector while navigating the competitive landscape.
Who Are JFNNX's Key Customers?
- Individual investors seeking exposure to the life sciences sector.
- Institutional investors, such as pension funds and endowments.
- Financial advisors who recommend the fund to their clients.
- Retirement savers looking for long-term growth opportunities.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is a fund, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 42 snapshots
| 2026-08-23 | 47 |
| 2026-08-31 | 47 |
| 2026-09-08 | 47 |
| 2026-09-16 | 47 |
| 2026-09-24 | 47 |
| 2026-10-04 | 47 |
| 2026-10-05 | 47 |
What changed?
The score has stayed at 47.
Over the same 30 days the stock moved -5.8%.
JFNNX Financials
Bull Case vs Bear Case
Bull Case
- Specialized focus on the high-growth life sciences sector.
- Experienced portfolio management team with expertise in healthcare investing.
- Established track record of delivering competitive investment performance.
- Diversified portfolio of life science stocks.
Bear Case
- Concentration risk due to focus on a single sector.
- Vulnerability to regulatory changes and clinical trial failures.
- Higher expense ratio compared to broader market index funds.
- Dependence on the performance of a limited number of holdings.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
JFNNX Latest News
No recent news available for JFNNX.
JFNNX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for JFNNX.
Price Targets
Wall Street price target analysis for JFNNX.
JFNNX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for JFNNX; grades run from A+ (80-100) to F (below 30).
Common Questions About JFNNX (Financials)
What are the main risks for JFNNX?
The main risks for JFNNX include sector concentration risk, as the fund's performance is heavily reliant on the life sciences industry.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- The information provided is based on available data and should not be considered investment advice.